Snowball logo
logo
SNN_logo

Smith & Nephew SNATS Inc

SNN โ€ข NYSE
$30.47-$0.36ย  (1.17%)
Estimate
P/E
20.7
EPS
1.47
Beta
0.671
Growth
Revenue, YoY
9.55%
Net income, YoY
41.59%
FCF, YoY
293.94%
Forecast
P/E (FWD)
12.7
EPS (FWD)
2.408
Dividends
Div. yield, TTM
2.61%
Annual payout, TTM
$0.79
Next ex. div date
October 2, 26
Payout
58.61%
Div.growth, 5y
1.15%
Dividend growth streak
2 y
Div.rating
About the company
Ticker
SNN
ISIN
US83175M2052
Country
United Kingdom
Sector (GICS)
Healthcare
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. The company operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. It offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. The company also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, it provides arthroscopic enabling technologies comprising fluid management equipment for surgical access, cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, the company offers advanced wound care products for the treatment and prevention of acute and chronic wounds, leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Frequently asked questions

What sector does Smith & Nephew SNATS Inc (SNN) operate in?

Smith & Nephew SNATS Inc belongs to the Healthcare sector and operates in the Medical Devices industry.

What is Smith & Nephew SNATS Inc (SNN) current stock price?

As of the latest data, Smith & Nephew SNATS Inc stock price is $30.47, with a previous close of $30.83. Smith & Nephew SNATS Inc lost -$0.36 in the last trading session, representing a -1.17% loss.

What is Smith & Nephew SNATS Inc (SNN) current market capitalization?

Smith & Nephew SNATS Inc market cap is approximately 12.75 billion.

What is Smith & Nephew SNATS Inc (SNN) Earnings Per Share (EPS)?

The trailing EPS is $1.47, and the forward EPS is $2.41.

What is Smith & Nephew SNATS Inc (SNN) Price-to-Earnings (P/E) ratio?

Smith & Nephew SNATS Inc current P/E ratio is 20.73, with a forward P/E of 12.65.

What is Smith & Nephew SNATS Inc (SNN) EBITDA?

Smith & Nephew SNATS Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is 748.00 million.

Does Smith & Nephew SNATS Inc (SNN) pay dividends?

Yes. Smith & Nephew SNATS Inc pays semiannual dividends with an annualized yield of 2.61% and an estimated annual payout of $0.79 per share.

When is the next ex-dividend date for Smith & Nephew SNATS Inc (SNN)?

The next ex-dividend date is scheduled for October 02, 2026.

What is Smith & Nephew SNATS Inc (SNN) beta (volatility) score?

Smith & Nephew SNATS Inc has a beta of 0.671, indicating lower volatility than the overall market.